Czajka Marcin, Pecold Krystyna
Katedra i Klinika Okulistyki Akademii Medycznej w Poznaniu.
Klin Oczna. 2002;104(1):59-62.
The aim of using enzymes in vitreoretinal surgery is to facility PVD and create pharmacological vitrectomy. It can be achieved by liquefying the gel structure of the vitreous (synchisis) and weakening of adherence of the posterior vitreous cortex to retina (syneresis). The article reviews currently used enzymes in vitreoretinal surgery (plasmin, hyaluronidase, dispase, chondroitinase, collagenase, urokinase, TPA--tissue plasminogen activator) and presents potential profits and side-effects related to their use. Although the day when vitreous surgery is replaced by pharmacological vitreolisis remains still as a future, these enzymes hold great promise. Additionally it has been proved that enzymes can be used successfully as an intraoperative adjuvant in vitrectomy.
在玻璃体视网膜手术中使用酶的目的是促进玻璃体后脱离(PVD)并实现药物性玻璃体切割。这可以通过液化玻璃体的凝胶结构(玻璃体分层)和削弱玻璃体后皮质与视网膜的粘连(玻璃体皱缩)来实现。本文回顾了目前在玻璃体视网膜手术中使用的酶(纤溶酶、透明质酸酶、分散酶、软骨素酶、胶原酶、尿激酶、组织型纤溶酶原激活剂——TPA),并介绍了与使用这些酶相关的潜在益处和副作用。尽管药物性玻璃体溶解取代玻璃体手术的日子仍在未来,但这些酶具有很大的前景。此外,已经证明酶可以成功地用作玻璃体切割术中的辅助剂。